Abbott and others pay $421 million to settle pricing fraud claims for US Medicare
This article was originally published in Scrip
Executive Summary
Abbott Laboratories, B Braun Medical and Boehringer Ingelheim's Roxane Laboratories have agreed to pay $421 million to settle accusations that they reported false and inflated prices for their products with the knowledge that the federal healthcare programmes, Medicare and Medicaid, would rely on them to set reimbursement rates.